Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
SALT LAKE CITY, Utah & BOULDER, Colo., April 27, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis' PARP inhibitor, Rubraca. Financial terms of the deal were not disclosed.Under the agreement, Myriad will submit a supplementary premarket approval (sPMA) application under its existing PMA for BRACAnalysis CDx to include Rubraca. The...
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 20, 2017--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter
2017 financial results on Wednesday, May 3, 2017, after the close of the
U.S. financial markets. Clovis’ senior management will host a conference
call and live audio webcast at 4:30 p.m. ET that day to discuss the
company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis
Abstracts provide new insights into rucaparib’s mechanism of action
and function in multiple disease and therapy settings
FDA approved Rubraca® (rucaparib) tablets
in late 2016 as monotherapy treatment for women with BRCA-mutated
advanced ovarian cancer
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 28, 2017--
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib
preclinical data will be presented at the Am...
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.